Hologic Bundle
Who Really Controls Hologic?
Understanding Hologic's SWOT Analysis begins with knowing who steers its ship. The ownership structure of Hologic, a leader in women's health, is a crucial factor in its strategic decisions and future growth. A deep dive into Hologic's ownership reveals key players influencing its trajectory.
This exploration into Hologic ownership will dissect its founding, the influence of institutional investors, and the impact of public shareholders. Examining who owns Hologic provides insights into its financial performance and strategic direction. Knowing the major shareholders and Hologic executives is essential for anyone interested in Hologic stock or understanding the company's long-term prospects, including its subsidiaries and market share.
Who Founded Hologic?
The specifics of the founding ownership of the company, including the names of the founders, their initial equity distribution, or the exact number of shares at the beginning, are not readily available in the provided search results from 2024-2025. Information regarding early investors, such as angel investors or family and friends who acquired stakes during the initial phase, is also absent from recent public filings and financial news.
Similarly, details about early agreements, such as vesting schedules, buy-sell clauses, or any initial ownership disputes, are not present in the available information. The focus of the available data is primarily on the company's current institutional ownership and recent developments as a publicly traded entity. Therefore, a comprehensive overview of the company's founding ownership structure is not possible based on the available sources.
The company's history and background, including its early ownership, is essential to understanding its trajectory. However, the limited information available emphasizes the importance of consulting a variety of sources to get a complete picture of the company's origins. For a deeper dive, one might need to consult historical archives or reach out to the company directly.
Founding Details
Precise details on the founders and their initial equity split are not available in recent public records. Information on early backers and initial agreements is also limited.
Publicly Traded Status
The focus of available information is on the company's current institutional ownership. The company is a publicly traded entity.
Data Limitations
Comprehensive historical information regarding the company's early ownership is not readily accessible. This limits the ability to provide a complete overview.
Further Research
To gain a more detailed understanding, one might need to consult historical archives or contact the company directly. This is important for a complete picture.
Focus of Data
The available data primarily focuses on the company's current institutional ownership and recent developments. This is a key area of information.
Importance of History
Understanding the company's history, including its early ownership, is vital. This information is key to understanding its trajectory.
Key Takeaways
The available information does not provide specific details about the founders or early ownership of the company. The focus is on current institutional ownership and recent developments. For more information, consult the Growth Strategy of Hologic.
- The company is publicly traded.
- Details on early investors are limited.
- Historical archives or direct contact with the company may be necessary for a complete picture.
- The company's current institutional ownership is the primary focus of available data.
Hologic SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Hologic’s Ownership Changed Over Time?
The ownership structure of the Hologic company, which trades on Nasdaq under the ticker HOLX, is primarily institutional. As of May 2025, institutional investors held approximately 98.43% of the company's shares. This demonstrates a strong presence of institutional investors in the company. This is a slight decrease from the 99.22% recorded in April 2025 and 101.02% in March 2025. The total number of institutional owners is 1445, holding a total of 259,970,168 shares.
Over the past few years, Hologic has been actively managing its share count. It has reduced diluted shares outstanding by nearly 31 million shares, from 269 million to 238 million. This reduction, along with share buybacks, indicates the company's commitment to delivering shareholder value. For instance, in the first quarter of fiscal 2025, Hologic repurchased 6.8 million shares for a total of $517 million. These actions, particularly the strong institutional presence, influence company strategy and governance, aligning with the long-term growth prospects of Hologic's focus on women's health, diagnostics, and surgical solutions.
| Shareholder | Ownership (as of March 31, 2025) | Shares Held |
|---|---|---|
| Vanguard Group Inc. | 12.03% | 26,815,519 |
| BlackRock, Inc. | 9.59% | 21,364,833 |
| T. Rowe Price Investment Management, Inc. | 7.94% | 17,688,478 |
| Morgan Stanley | 4.58% | 10,208,782 |
| State Street Corp | 4.54% | 10,113,103 |
Insider ownership, reflecting holdings by company executives and directors, was approximately 0.68% in May 2025. Carl C. Icahn is the largest individual Hologic shareholder, owning 28.15 million shares, which represents 12.63% of the company as of June 12, 2025. This significant individual stake contrasts with the broader institutional dominance. For more details on how the company operates, you can check out the Marketing Strategy of Hologic.
Key Takeaways
The ownership of Hologic is heavily influenced by institutional investors, reflecting confidence in the company's future.
- Institutional investors hold the majority of the shares.
- The company has been actively managing its share count.
- Carl C. Icahn is the largest individual shareholder.
- Hologic is a publicly traded company.
Hologic PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Hologic’s Board?
The Board of Directors at the Hologic company plays a vital role in its governance. As of January 2025, the board was set to consist of eight directors following the retirements of Sally W. Crawford and Scott T. Garrett. Wayde McMillan was elected to the Board, effective April 4, 2025, and appointed to the Audit and Finance Committee. This structure ensures a balance of experience and fresh perspectives within the leadership.
Who owns Hologic is a key question, and the board's composition reflects the company's structure. Stephen P. MacMillan serves as Chairman, President, and Chief Executive Officer. Amy M. Wendell, an independent director, serves as the Lead Independent Director. This setup provides a balance between executive leadership and independent oversight, which is crucial for Hologic investors and the overall health of the Hologic company.
| Director | Position | Key Role |
|---|---|---|
| Stephen P. MacMillan | Chairman, President, and CEO | Overall Leadership and Strategy |
| Amy M. Wendell | Lead Independent Director | Independent Oversight |
| Wayde McMillan | Director | Audit and Finance Committee |
The significant institutional ownership, exceeding 97%, highlights the voting power of major Hologic investors. These investors can influence company decisions through their voting rights at annual meetings. Management regularly engages with stockholders to discuss business strategy, executive compensation, and ESG progress, with feedback shared with the Board. This engagement is a key part of how Hologic executives and the board manage the company. To learn more about the company's strategic direction, you can read about the Growth Strategy of Hologic.
Key Takeaways on Hologic's Board and Ownership
The board's structure balances executive leadership with independent oversight.
- Institutional investors hold significant voting power.
- Management actively engages with stockholders.
- The board is responsible for the company's strategic direction.
Hologic Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Hologic’s Ownership Landscape?
In the past few years, the ownership structure of the Hologic company has evolved through strategic initiatives. The company has focused on returning value to its shareholders, as evidenced by significant share repurchase programs. For instance, in the first quarter of fiscal 2025, Hologic repurchased 6.8 million shares for $517 million. Over a five-year period, the company reduced its share count by nearly 31 million shares, decreasing from 269 million to 238 million diluted shares outstanding. These actions reflect a commitment to enhancing shareholder value through capital allocation strategies.
From a mergers and acquisitions (M&A) perspective, Hologic finalized the acquisition of Gynesonics in early fiscal 2025 for $350 million, expanding its women's health solutions portfolio. This strategic move, along with other initiatives, underscores Hologic's dedication to diversifying its revenue streams and solidifying its market position. Leadership transitions have also been notable, with key executive appointments and retirements influencing the company's direction. These developments collectively shape the ownership profile and strategic trajectory of the Hologic company.
| Metric | Details | Year |
|---|---|---|
| Share Repurchases | 6.8 million shares for $517 million | Fiscal Q1 2025 |
| Share Count Reduction | Nearly 31 million shares | Past 5 years |
| Institutional Ownership | Over 97% of shares | May 2025 |
Institutional investors hold over 97% of Hologic's shares as of May 2025, indicating strong confidence from major investors. This high level of institutional ownership can significantly impact the stock's price due to their trading activities. Furthermore, Hologic's management aims for 5% to 7% organic revenue growth in constant currency (excluding COVID-19 impact) through 2025, demonstrating a forward-looking strategy aimed at sustained financial performance for its stockholders. If you are interested in learning more, you can read about the Hologic company.
Key Acquisitions
Gynesonics acquisition in early fiscal 2025 for $350 million expanded Hologic's women's health solutions.
Leadership Changes
John Griffin retired as General Counsel, Anne Liddy assumed the role, and Wayde McMillan joined the Board of Directors.
Shareholder Value
Share buybacks and a focus on organic revenue growth indicate a commitment to shareholder returns.
Future Outlook
Management targets 5% to 7% organic revenue growth in constant currency through 2025.
Hologic Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Hologic Company?
- What is Competitive Landscape of Hologic Company?
- What is Growth Strategy and Future Prospects of Hologic Company?
- How Does Hologic Company Work?
- What is Sales and Marketing Strategy of Hologic Company?
- What is Brief History of Hologic Company?
- What is Customer Demographics and Target Market of Hologic Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.